Sagace Wealth Management LLC Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Sagace Wealth Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.6% in the 4th quarter, HoldingsChannel reports. The firm owned 3,620 shares of the company’s stock after selling 254 shares during the period. Sagace Wealth Management LLC’s holdings in Johnson & Johnson were worth $524,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in JNJ. Virtu Financial LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $1,082,000. Sienna Gestion raised its stake in Johnson & Johnson by 18.5% during the second quarter. Sienna Gestion now owns 100,741 shares of the company’s stock worth $14,717,000 after purchasing an additional 15,761 shares during the period. Paces Ferry Wealth Advisors LLC raised its stake in Johnson & Johnson by 2.0% during the second quarter. Paces Ferry Wealth Advisors LLC now owns 8,087 shares of the company’s stock worth $1,182,000 after purchasing an additional 157 shares during the period. Altrius Capital Management Inc raised its stake in Johnson & Johnson by 12.8% during the second quarter. Altrius Capital Management Inc now owns 28,222 shares of the company’s stock worth $4,125,000 after purchasing an additional 3,210 shares during the period. Finally, Miramar Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $258,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $147.78 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market cap of $355.79 billion, a PE ratio of 21.39, a PEG ratio of 2.30 and a beta of 0.51. The company’s 50-day moving average is $148.86 and its two-hundred day moving average is $156.01.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the company posted $2.66 EPS. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.36%. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Bank of America reaffirmed a “neutral” rating and issued a $166.00 price target on shares of Johnson & Johnson in a report on Tuesday, December 10th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.